Jose F. Ponte

Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder

Hamid M. Abdolmaleky, Kuang‐Hung Cheng, Stephen V. Faraone et al. · Human Molecular Genetics · 2006 · 460 citations · Full text

Life Sciences, Genetics, Psychiatry +12

Effects of Drug–Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody–Maytansinoid Conjugates

Xiuxia Sun, Jose F. Ponte, Nicholas C. Yoder et al. · Bioconjugate Chemistry · 2017 · 253 citations

Pharmacy, Oncology, Pharmacology +17

Differential DNA Hypermethylation of Critical Genes Mediates the Stage-Specific Tobacco Smoke-Induced Neoplastic Progression of Lung Cancer

Andrea Russo, Arunthathi Thiagalingam, Hongjie Pan et al. · Clinical Cancer Research · 2005 · 147 citations

Medicine, Genetics, Oncology +17

Phase 1 dose‐escalation study of mirvetuximab soravtansine (<scp>IMGN853</scp>), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors

Kathleen N. Moore, Hossein Borghaei, David M. O’Malley et al. · Cancer · 2017 · 141 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models

Jose F. Ponte, Olga Ab, Leanne Lanieri et al. · Neoplasia · 2016 · 112 citations · Full text

Medicine, Oncology, Pharmacology +16